

Supplementary material

Clinical sequencing yield in epilepsy, autism spectrum disorder, and intellectual disability

A systematic review and meta-analysis

Arthur Stefanski, Yamile Calle-Lopez, Costin Leu, Eduardo Pérez-Palma, Elia Pestana-Knight, Dennis Lal

Corresponding author:

Dennis Lal, PhD

Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic
Cleveland, OH 44195, US

Tel: +1 216 704 1519

Email: lald@ccf.org


1. Supplementary Figures	4
1.1. Overall and by disorder	4
1.1.1. Figure e-1. Forest plot of meta-analysis of the diagnostic yield over all epilepsy studies (adjusted)	4
1.1.2. Figure e-2. Funnel plot over all epilepsy studies (adjusted)	5
1.1.3. Figure e-3. Forest plot of meta-analysis of the diagnostic yield over all ASD studies (adjusted)	6
1.1.4. Figure e-4. Funnel plot over all ASD studies (adjusted)	6
1.1.5. Figure e-5. Forest plot of meta-analysis of the diagnostic yield over all ID studies (adjusted)	7
1.1.6. Figure e-6. Funnel plot over all ID studies (adjusted)	8
1.1.7. Figure e-7. Error bar plot by disorder (adjusted)	8
1.2. By epilepsy subtype	9
1.2.1. Figure e-8. Forest plot of meta-analysis of the diagnostic yield over all GE studies (adjusted)	9
1.2.2. Figure e-9. Funnel plot over all GE studies (adjusted)	9
1.2.3. Figure e-10. Forest plot of meta-analysis of the diagnostic yield over all FE studies (adjusted)	10
1.2.4. Figure e-11. Funnel plot over all FE studies (adjusted)	10
1.2.5. Figure e-12. Forest plot of meta-analysis of the diagnostic yield over all GE&FE studies (adjusted)	11
1.2.6. Figure e-13. Funnel plot over all GE&FE studies (adjusted)	12
1.3. By disorder subtype	12
1.3.1. Figure e-14. Forest plot of meta-analysis of the diagnostic yield over all ASD with ID or DD studies	12
1.3.2. Figure e-15. Funnel plot over all ASD with ID or DD studies	13
1.3.3. Figure e-16. Forest plot of meta-analysis of the diagnostic yield over all WS studies (adjusted)	13
1.3.4. Figure e-17. Funnel plot over all West syndrome studies (adjusted)	14
1.3.5. Figure e-18. Error bar plot by subtype (adjusted)	14
1.4. By technology	15
1.4.1. Figure e-19. Forest plot of meta-analysis of the diagnostic yield over all Panel studies (adjusted)	15

1.4.2.	Figure e-20. Forest plot of meta-analysis of the diagnostic yield over all ES studies (adjusted)	16
1.4.3.	Figure e-21. Funnel plot over all Panel studies (adjusted)	17
1.4.4.	Figure e-22. Funnel plot over all ES studies (adjusted)	18
1.4.5.	Figure e-23. Error bar plot by technology (adjusted)	18
1.5. Reported genes		19
1.5.1.	Figure e-24. Number and rate of genes with pathogenic variants	19
2. References of all studies included in meta-analysis		20-26

1. Supplementary Figures

1.1. Overall and by disorder


1.1.1. Figure e-1. Forest plot of meta-analysis of the diagnostic yield over all epilepsy studies (adjusted)



Abbreviations: CI = confidence interval, Filled: ... = study added by the trim and fill method, TE = estimated treatment effect, TEse = standard error of estimated treatment effect, I^2 = estimated


proportion of the variance in study estimates that is due to heterogeneity, τ^2 = estimate of between-study variance, to quantify heterogeneity, Proportion = fraction of individuals with a positive genetic test, i.e. pathogenic or likely pathogenic variant.

1.1.2. Figure e-2. Funnel plot over all epilepsy studies (adjusted)




Grey dots = Original studies, White dots = Filled in studies based on the trim and fill method by Duval & Tweedie.

1.1.3. Figure e-3. Forest plot of meta-analysis of the diagnostic yield over all ASD studies (adjusted)




Abbreviations: CI = confidence interval, I^2 = estimated proportion of the variance in study estimates that is due to heterogeneity, τ^2 = estimate of between-study variance, to quantify heterogeneity, Proportion = fraction of individuals with a positive genetic test, i.e. pathogenic or likely pathogenic variant.

1.1.4. Figure e-4. Funnel plot over all ASD studies (adjusted)




Grey dots = Original studies, White dots = Filled in studies based on the trim and fill method by Duval & Tweedie.

1.1.5. Figure e-5. Forest plot of meta-analysis of the diagnostic yield over all ID studies (adjusted)




Abbreviations: CI = confidence interval, I^2 = estimated proportion of the variance in study estimates that is due to heterogeneity, τ^2 = estimate of between-study variance, to quantify heterogeneity, Proportion = fraction of individuals with a positive genetic test, i.e. pathogenic or likely pathogenic variant.

1.1.6. Figure e-6. Funnel plot over all ID studies (adjusted)



Grey dots = Original studies, White dots = Filled in studies based on the trim and fill method by Duval & Tweedie.


1.1.7. Figure e-7. Error bar plot by disorder (adjusted)



Abbreviations: ASD = autism spectrum disorder, ID = intellectual disability.


1.2. By epilepsy subtype

1.2.1. Figure e-8. Forest plot of meta-analysis of the diagnostic yield over all GE studies (adjusted)




Abbreviations: CI = confidence interval, I^2 = estimated proportion of the variance in study estimates that is due to heterogeneity, τ^2 = estimate of between-study variance, to quantify heterogeneity, Proportion = fraction of individuals with a positive genetic test, i.e. pathogenic or likely pathogenic variant.

1.2.2. Figure e-9. Funnel plot over all GE studies (adjusted)




Grey dots = Original studies, White dots = Filled in studies based on the trim and fill method by Duval & Tweedie.

1.2.3. Figure e-10. Forest plot of meta-analysis of the diagnostic yield over all FE studies (adjusted)




Abbreviations: CI = confidence interval, I^2 = estimated proportion of the variance in study estimates that is due to heterogeneity, τ^2 = estimate of between-study variance, to quantify heterogeneity, Proportion = fraction of individuals with a positive genetic test, i.e. pathogenic or likely pathogenic variant.

1.2.4. Figure e-11. Funnel plot over all FE studies (adjusted)



Grey dots = Original studies, White dots = Filled in studies based on the trim and fill method by Duval & Tweedie.


1.2.5. Figure e-12. Forest plot of meta-analysis of the diagnostic yield over all GE&FE studies
(adjusted)



Abbreviations: CI = confidence interval, I^2 = estimated proportion of the variance in study estimates that is due to heterogeneity, τ^2 = estimate of between-study variance, to quantify heterogeneity,

Proportion = fraction of individuals with a positive genetic test, i.e. pathogenic or likely pathogenic variant.


1.2.6. Figure e-13. Funnel plot over all GE&FE studies (adjusted)



Grey dots = Original studies, White dots = Filled in studies based on the trim and fill method by Duval & Tweedie.


1.3. By disorder subtype

1.3.1. Figure e-14. Forest plot of meta-analysis of the diagnostic yield over all ASD with ID or DD studies




Abbreviations: CI = confidence interval, I^2 = estimated proportion of the variance in study estimates that is due to heterogeneity, τ^2 = estimate of between-study variance, to quantify heterogeneity, Proportion = fraction of individuals with a positive genetic test, i.e. pathogenic or likely pathogenic variant.

1.3.2. Figure e-15. Funnel plot over all ASD with ID or DD studies




Grey dots = Original studies, White dots = No study fill needed based on the trim and fill method by Duval & Tweedie.

1.3.3. Figure e-16. Forest plot of meta-analysis of the diagnostic yield over all West syndrome studies (adjusted)




Abbreviations: CI = confidence interval, I^2 = estimated proportion of the variance in study estimates that is due to heterogeneity, τ^2 = estimate of between-study variance, to quantify heterogeneity, Proportion = fraction of individuals with a positive genetic test, i.e. pathogenic or likely pathogenic variant.

1.3.4. Figure e-17. Funnel plot over all West syndrome studies (adjusted)



Grey dots = Original studies, White dots = Filled in studies based on the trim and fill method by Duval & Tweedie.


1.3.5. Figure e-18. Error bar plot by subtype (adjusted)



Abbreviations: GE&FE = combined generalized and focal epilepsy, FE = focal epilepsy, GE = generalized epilepsy, WS = West syndrome, ASD with ID or DD = autism spectrum disorder with intellectual disability or developmental delay.

1.4. By technology


1.4.1. Figure e-19. Forest plot of meta-analysis of the diagnostic yield over all Panel studies (adjusted)



Abbreviations: CI = confidence interval, I^2 = estimated proportion of the variance in study estimates that is due to heterogeneity, τ^2 = estimate of between-study variance, to quantify


heterogeneity, *Proportion* = fraction of individuals with a positive genetic test, i.e. pathogenic or likely pathogenic variant.

1.4.2. Figure e-20. Funnel plot over all Panel studies (adjusted)




Grey dots = Original studies, White dots = Filled in studies based on the trim and fill method by Duval & Tweedie.

1.4.3. Figure e-21. Forest plot of meta-analysis of the diagnostic yield over all ES studies (adjusted)




Abbreviations: CI = confidence interval, I^2 = estimated proportion of the variance in study estimates that is due to heterogeneity, τ^2 = estimate of between-study variance, to quantify heterogeneity, Proportion = fraction of individuals with a positive genetic test, i.e. pathogenic or likely pathogenic variant.

1.4.4. Figure e-22. Funnel plot over all ES studies (adjusted)



Grey dots = Original studies, White dots = Filled in studies based on the trim and fill method by Duval & Tweedie.

1.4.5. Figure e-23. Error bar plot by technology (adjusted)




The diagnostic yield across Panel and ES.

Abbreviations: Panel = targeted gene panel sequencing, ES = exome sequencing.

1.5. Reported genes

1.5.1. Figure e-24. Total number and rate of reported genes with pathogenic variants separated by disorder



The bars represent the number of genes with pathogenic variants. The line represents the rate of genes per month and year. The number of identified genes increased rapidly in recent years for epilepsy. For ASD and ID the number of reported genes with pathogenic variants is low.

Abbreviations: ASD = autism spectrum disorder, ID = intellectual disability, * = Data were collected until July 19, 2019.

2. References

1. Allen NM, Conroy J, Shahwan A, et al. Unexplained early onset epileptic encephalopathy: Exome screening and phenotype expansion. *Epilepsia*. 2016;57:e12–e17.
2. Alvarez-Mora MI, Calvo Escalona R, Puig Navarro O, et al. Comprehensive molecular testing in patients with high functioning autism spectrum disorder. *Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis*. 2016;784–785:46–52.
3. Angione K, Eschbach K, Smith G, Joshi C, Demarest S. Genetic testing in a cohort of patients with potential epilepsy with myoclonic-atonic seizures. *Epilepsy Research*. 2019;150:70–77.
4. Arafat A, Jing P, Ma Y, et al. Unexplained Early Infantile Epileptic Encephalopathy in Han Chinese Children: Next-Generation Sequencing and Phenotype Enriching. *Sci Rep*. 2017;7:46227.
5. Aspromonte MC, Bellini M, Gasparini A, et al. Characterization of intellectual disability and autism comorbidity through gene panel sequencing. *Hum Mutat*. Epub 2019 Jun 17.
6. Balciuniene J, DeChene ET, Akgumus G, et al. Use of a Dynamic Genetic Testing Approach for Childhood-Onset Epilepsy. *JAMA Netw Open*. 2019;2:e192129.
7. Bi C, Wu J, Jiang T, et al. Mutations of *ANK3* identified by exome sequencing are associated with autism susceptibility. *Hum Mutat*. 2012;33:1635–1638.
8. Butler KM, da Silva C, Alexander JJ, Hegde M, Escayg A. Diagnostic Yield From 339 Epilepsy Patients Screened on a Clinical Gene Panel. *Pediatric Neurology*. 2017;77:61–66.
9. Callaghan DB, Rogic S, Tan PPC, et al. Whole genome sequencing and variant discovery in the ASPIRE autism spectrum disorder cohort. *Clin Genet*. Epub 2019 Apr 30.:cge.13556.
10. Cerebral Calcification International Study Group, Tonduti D, Panteghini C, et al. Encephalopathies with intracranial calcification in children: clinical and genetic characterization. *Orphanet J Rare Dis*. 2018;13:135.
11. Chérot E, Keren B, Dubourg C, et al. Using medical exome sequencing to identify the causes of neurodevelopmental disorders: Experience of 2 clinical units and 216 patients: CHÉROT et al. *Clin Genet*. 2018;93:567–576.
12. Codina-Solà M, Rodríguez-Santiago B, Homs A, et al. Integrated analysis of whole-exome sequencing and transcriptome profiling in males with autism spectrum disorders. *Molecular Autism*. 2015;6:21.

13. de Ligt J, Willemsen MH, van Bon BWM, et al. Diagnostic Exome Sequencing in Persons with Severe Intellectual Disability. *N Engl J Med*. 2012;367:1921–1929.
14. Du X, Gao X, Liu X, et al. Genetic Diagnostic Evaluation of Trio-Based Whole Exome Sequencing Among Children With Diagnosed or Suspected Autism Spectrum Disorder. *Front Genet*. 2018;9:594.
15. Epilepsy Genetics Initiative. The Epilepsy Genetics Initiative: Systematic reanalysis of diagnostic exomes increases yield. *Epilepsia*. 2019;60:797–806.
16. Fung C-W, Kwong AK-Y, Wong VC-N. Gene panel analysis for nonsyndromic cryptogenic neonatal/infantile epileptic encephalopathy. *Epilepsia Open*. 2017;2:236–243.
17. Gieldon L, Mackenroth L, Kahlert A-K, et al. Diagnostic value of partial exome sequencing in developmental disorders. Kaya N, editor. *PLoS ONE*. 2018;13:e0201041.
18. Gilissen C, Hehir-Kwa JY, Thung DT, et al. Genome sequencing identifies major causes of severe intellectual disability. *Nature*. 2014;511:344–347.
19. Gokben S, Onay H, Yilmaz S, et al. Targeted next generation sequencing: the diagnostic value in early-onset epileptic encephalopathy. *Acta Neurol Belg*. 2017;117:131–138.
20. Grozeva D, Carss K, Spasic-Boskovic O, et al. Targeted Next-Generation Sequencing Analysis of 1,000 Individuals with Intellectual Disability: HUMAN MUTATION. *Human Mutation*. 2015;36:1197–1204.
21. Halvardson J, Zhao JJ, Zaghlool A, et al. Mutations in *HECW2* are associated with intellectual disability and epilepsy. *J Med Genet*. 2016;53:697–704.
22. Hamdan FF, Myers CT, Cossette P, et al. High Rate of Recurrent De Novo Mutations in Developmental and Epileptic Encephalopathies. *The American Journal of Human Genetics*. 2017;101:664–685.
23. Han JY, Jang JH, Park J, Lee IG. Targeted Next-Generation Sequencing of Korean Patients With Developmental Delay and/or Intellectual Disability. *Front Pediatr*. 2018;6:391.
24. Han JY, Jang W, Park J, Kim M, Kim Y, Lee IG. Diagnostic approach with genetic tests for global developmental delay and/or intellectual disability: Single tertiary center experience. *Annals of Human Genetics*. 2019;83:115–123.
25. Helbig KL, Farwell Hagman KD, Shinde DN, et al. Diagnostic exome sequencing provides a molecular diagnosis for a significant proportion of patients with epilepsy. *Genet Med*. 2016;18:898–905.

26. Hesse AN, Bevilacqua J, Shankar K, Reddi HV. Retrospective genotype-phenotype analysis in a 305 patient cohort referred for testing of a targeted epilepsy panel. *Epilepsy Research*. 2018;144:53–61.
27. Hildebrand MS, Myers CT, Carvill GL, et al. A targeted resequencing gene panel for focal epilepsy. *Neurology*. 2016;86:1605–1612.
28. Ji J, Shen L, Bootwalla M, et al. A semi-automated whole exome sequencing workflow leads to increased diagnostic yield and identification of novel candidate variants. *Molecular Case Studies*. 2019;5:mcs.a003756.
29. Kalsner L, Twachtman-Bassett J, Tokarski K, et al. Genetic testing including targeted gene panel in a diverse clinical population of children with autism spectrum disorder: Findings and implications. *Mol Genet Genomic Med*. 2018;6:171–185.
30. Kim SH, Kim B, Lee JS, et al. Proband-Only Clinical Exome Sequencing for Neurodevelopmental Disabilities. *Pediatric Neurology*. Epub 2019 Feb.:S0887899418313481.
31. Kodera H, Kato M, Nord AS, et al. Targeted capture and sequencing for detection of mutations causing early onset epileptic encephalopathy. *Epilepsia*. 2013;54:1262–1269.
32. Kwong AK-Y, Ho AC-C, Fung C-W, Wong VC-N. Analysis of mutations in 7 genes associated with neuronal excitability and synaptic transmission in a cohort of children with non-syndromic infantile epileptic encephalopathy. *PLoS ONE*. 2015;10:e0126446.
33. Lee CG, Lee J, Lee M. Multi-gene panel testing in Korean patients with common genetic generalized epilepsy syndromes. Russo E, editor. *PLoS ONE*. 2018;13:e0199321.
34. Lemke JR, Riesch E, Scheurenbrand T, et al. Targeted next generation sequencing as a diagnostic tool in epileptic disorders: Epilepsy Panel. *Epilepsia*. 2012;53:1387–1398.
35. Lindy AS, Stosser MB, Butler E, et al. Diagnostic outcomes for genetic testing of 70 genes in 8565 patients with epilepsy and neurodevelopmental disorders. *Epilepsia*. 2018;59:1062–1071.
36. Liu J, Tong L, Song S, et al. Novel and de novo mutations in pediatric refractory epilepsy. *Mol Brain*. 2018;11:48.
37. Long S, Zhou H, Li S, et al. The Clinical and Genetic Features of Co-occurring Epilepsy and Autism Spectrum Disorder in Chinese Children. *Front Neurol*. 2019;10:505.
38. Mercimek-Mahmutoglu S, Patel J, Cordeiro D, et al. Diagnostic yield of genetic testing in epileptic encephalopathy in childhood. *Epilepsia*. 2015;56:707–716.

39. Miao P, Feng J, Guo Y, et al. Genotype and phenotype analysis using an epilepsy-associated gene panel in Chinese pediatric epilepsy patients. *Clin Genet*. 2018;94:512–520.
40. Michaud JL, Lachance M, Hamdan FF, et al. The genetic landscape of infantile spasms. *Human Molecular Genetics*. 2014;23:4846–4858.
41. Møller RS, Larsen LHG, Johannesen KM, et al. Gene Panel Testing in Epileptic Encephalopathies and Familial Epilepsies. *Mol Syndromol*. 2016;7:210–219.
42. Morgan A, Gandin I, Belcaro C, et al. Target sequencing approach intended to discover new mutations in non-syndromic intellectual disability. *Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis*. 2015;781:32–36.
43. Muona M, Berkovic SF, Dibbens LM, et al. A recurrent de novo mutation in KCNC1 causes progressive myoclonus epilepsy. *Nat Genet*. 2015;47:39–46.
44. Oates S, Tang S, Rosch R, et al. Incorporating epilepsy genetics into clinical practice: a 360° evaluation. *npj Genomic Med*. 2018;3:13.
45. Ortega-Moreno L, Giráldez BG, Soto-Insuga V, et al. Molecular diagnosis of patients with epilepsy and developmental delay using a customized panel of epilepsy genes. Russo E, editor. *PLoS ONE*. 2017;12:e0188978.
46. Palmer EE, Schofield D, Shrestha R, et al. Integrating exome sequencing into a diagnostic pathway for epileptic encephalopathy: Evidence of clinical utility and cost effectiveness. *Mol Genet Genomic Med*. 2018;6:186–199.
47. Papuc SM, Abela L, Steindl K, et al. The role of recessive inheritance in early-onset epileptic encephalopathies: a combined whole-exome sequencing and copy number study. *Eur J Hum Genet*. 2019;27:408–421.
48. Parrini E, Marini C, Mei D, et al. Diagnostic Targeted Resequencing in 349 Patients with Drug-Resistant Pediatric Epilepsies Identifies Causative Mutations in 30 Different Genes: HUMAN MUTATION. *Human Mutation*. 2017;38:216–225.
49. Pেকেles H, Accogli A, Boudrahem-Addour N, Russell L, Parente F, Srour M. Diagnostic Yield of Intellectual Disability Gene Panels. *Pediatric Neurology*. 2019;92:32–36.
50. Perucca P, Scheffer IE, Harvey AS, et al. Real-world utility of whole exome sequencing with targeted gene analysis for focal epilepsy. *Epilepsy Research*. 2017;131:1–8.
51. Prasad A, Sdano MA, Vanzo RJ, et al. Clinical utility of exome sequencing in individuals with large homozygous regions detected by chromosomal microarray analysis. *BMC Med Genet*. 2018;19:46.

52. Rim JH, Kim SH, Hwang IS, et al. Efficient strategy for the molecular diagnosis of intractable early-onset epilepsy using targeted gene sequencing. *BMC Med Genomics*. 2018;11:6.
53. Rossi M, El-Khechen D, Black MH, Farwell Hagman KD, Tang S, Powis Z. Outcomes of Diagnostic Exome Sequencing in Patients With Diagnosed or Suspected Autism Spectrum Disorders. *Pediatric Neurology*. 2017;70:34-43.e2.
54. Routier L, Verny F, Barcia G, et al. Exome sequencing findings in 27 patients with myoclonic-atonic epilepsy: Is there a major genetic factor? *Clin Genet*. 2019;96:254–260.
55. Segal E, Pedro H, Valdez-Gonzalez K, et al. Diagnostic Yield of Epilepsy Panels in Children With Medication-Refractory Epilepsy. *Pediatric Neurology*. 2016;64:66–71.
56. Shellhaas RA, Wusthoff CJ, Tsuchida TN, et al. Profile of neonatal epilepsies: Characteristics of a prospective US cohort. *Neurology*. 2017;89:893–899.
57. Snoeijen-Schouwenaars FM, van Ool JS, Verhoeven JS, et al. Diagnostic exome sequencing in 100 consecutive patients with both epilepsy and intellectual disability. *Epilepsia*. 2019;60:155–164.
58. Srivastava S, Cohen JS, Vernon H, et al. Clinical whole exome sequencing in child neurology practice: WES in Child Neurology. *Ann Neurol*. 2014;76:473–483.
59. Staněk D, Laššuthová P, Štěrbová K, et al. Detection rate of causal variants in severe childhood epilepsy is highest in patients with seizure onset within the first four weeks of life. *Orphanet J Rare Dis*. 2018;13:71.
60. Symonds JD, Zuberi SM, Stewart K, et al. Incidence and phenotypes of childhood-onset genetic epilepsies: a prospective population-based national cohort. *Brain* [online serial]. Accessed at: <https://academic.oup.com/brain/advance-article/doi/10.1093/brain/awz195/5532195>. Accessed July 17, 2019.
61. Tammimies K, Marshall CR, Walker S, et al. Molecular Diagnostic Yield of Chromosomal Microarray Analysis and Whole-Exome Sequencing in Children With Autism Spectrum Disorder. *JAMA*. 2015;314:895.
62. Tan CA, Topper S, del Gaudio D, et al. Characterization of patients referred for non-specific intellectual disability testing: the importance of autosomal genes for diagnosis: Characterization of patients referred for non-specific ID testing. *Clin Genet*. 2016;89:478–483.
63. Thevenon J, Duffourd Y, Masurel-Paulet A, et al. Diagnostic odyssey in severe neurodevelopmental disorders: toward clinical whole-exome sequencing as a first-line diagnostic test: Diagnostic odyssey in severe neurodevelopmental disorders. *Clin Genet*. 2016;89:700–707.

64. Trump N, McTague A, Brittain H, et al. Improving diagnosis and broadening the phenotypes in early-onset seizure and severe developmental delay disorders through gene panel analysis. *J Med Genet*. 2016;53:310–317.
65. Truty R, Patil N, Sankar R, et al. Possible precision medicine implications from genetic testing using combined detection of sequence and intragenic copy number variants in a large cohort with childhood epilepsy. *Epilepsia Open* [online serial]. 0. Accessed at: <https://onlinelibrary.wiley.com/doi/abs/10.1002/epi4.12348>. Accessed July 16, 2019.
66. Tsai M-H, Chan C-K, Chang Y-C, et al. Molecular Genetic Characterization of Patients With Focal Epilepsy Using a Customized Targeted Resequencing Gene Panel. *Front Neurol*. 2018;9:515.
67. Tsang MH-Y, Leung GK-C, Ho AC-C, et al. Exome sequencing identifies molecular diagnosis in children with drug-resistant epilepsy. *Epilepsia Open*. 2019;4:63–72.
68. Tumiené B, Maver A, Writzl K, et al. Diagnostic exome sequencing of syndromic epilepsy patients in clinical practice. *Clin Genet*. 2018;93:1057–1062.
69. Vrijenhoek T, Middelburg EM, Monroe GR, et al. Whole-exome sequencing in intellectual disability; cost before and after a diagnosis. *Eur J Hum Genet*. 2018;26:1566–1571.
70. Wang J, Gotway G, Pascual JM, Park JY. Diagnostic Yield of Clinical Next-Generation Sequencing Panels for Epilepsy. *JAMA Neurol*. 2014;71:650.
71. Wang J, Wen Y, Zhang Q, et al. Gene mutational analysis in a cohort of Chinese children with unexplained epilepsy: Identification of a new KCND3 phenotype and novel genes causing Dravet syndrome. *Seizure*. 2019;66.
72. Wirrell EC, Shellhaas RA, Joshi C, et al. How should children with West syndrome be efficiently and accurately investigated? Results from the National Infantile Spasms Consortium. *Epilepsia*. 2015;56:617–625.
73. Xiao B, Qiu W, Ji X, et al. Marked yield of re-evaluating phenotype and exome/target sequencing data in 33 individuals with intellectual disabilities. *Am J Med Genet*. 2018;176:107–115.
74. Yamamoto T, Imaizumi T, Yamamoto-Shimojima K, et al. Genomic backgrounds of Japanese patients with undiagnosed neurodevelopmental disorders. *Brain Dev*. Epub 2019 Jun 3.
75. Yang L, Kong Y, Dong X, et al. Clinical and genetic spectrum of a large cohort of children with epilepsy in China. *Genet Med*. 2019;21:564–571.
76. Zhang Q, Li J, Zhao Y, Bao X, Wei L, Wang J. Gene mutation analysis of 175 Chinese patients with early-onset epileptic encephalopathy: Gene mutation analysis of Chinese patients with EOEEs. *Clin Genet*. 2017;91:717–724.

77. Zhang Y, Kong W, Gao Y, et al. Gene Mutation Analysis in 253 Chinese Children with Unexplained Epilepsy and Intellectual/Developmental Disabilities. Shapiro MS, editor. PLoS ONE. 2015;10:e0141782.
78. Zhou P, He N, Zhang J-W, et al. Novel mutations and phenotypes of epilepsy-associated genes in epileptic encephalopathies. *Genes, Brain and Behavior*. 2018;17:e12456.
79. Zhou W-Z, Zhang J, Li Z, et al. Targeted resequencing of 358 candidate genes for autism spectrum disorder in a Chinese cohort reveals diagnostic potential and genotype-phenotype correlations. *Hum Mutat*. 2019;40:801–815.